Journal Description
Current Oncology
Current Oncology
is an international, peer-reviewed, open access journal published online by MDPI (from Volume 28 Issue 1-2021). Established in 1994, the journal represents a multidisciplinary medium for clinical oncologists to report and review progress in the management of this disease. The Canadian Association of Medical Oncologists (CAMO), the Canadian Association of Psychosocial Oncology (CAPO), the Canadian Association of General Practitioners in Oncology (CAGPO), the Cell Therapy Transplant Canada (CTTC), the Canadian Leukemia Study Group (CLSG) and others are affiliated with the journal and their members receive a discount on the article processing charges.
- Open Access— free for readers, with article processing charges (APC) paid by authors or their institutions.
- High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.
- Journal Rank: JCR - Q2 (Oncology)
- Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2024).
- Recognition of Reviewers: APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.
Impact Factor:
2.8 (2023);
5-Year Impact Factor:
2.9 (2023)
Latest Articles
AI-Enhanced Healthcare: Integrating ChatGPT-4 in ePROs for Improved Oncology Care and Decision-Making: A Pilot Evaluation
Curr. Oncol. 2025, 32(1), 7; https://doi.org/10.3390/curroncol32010007 (registering DOI) - 26 Dec 2024
Abstract
Background: Since 2023, ChatGPT-4 has been impactful across several sectors including healthcare, where it aids in medical information analysis and education. Electronic patient-reported outcomes (ePROs) play a crucial role in monitoring cancer patients’ post-treatment symptoms, enabling early interventions. However, managing the voluminous ePRO
[...] Read more.
Background: Since 2023, ChatGPT-4 has been impactful across several sectors including healthcare, where it aids in medical information analysis and education. Electronic patient-reported outcomes (ePROs) play a crucial role in monitoring cancer patients’ post-treatment symptoms, enabling early interventions. However, managing the voluminous ePRO data presents significant challenges. This study assesses the feasibility of utilizing ChatGPT-4 for analyzing side effect data from ePROs. Methods: Thirty cancer patients were consecutively collected via a web-based ePRO platform, reporting side effects over 4 weeks. ChatGPT-4, simulating oncologists, dietitians, and nurses, analyzed this data and offered improvement suggestions, which were then reviewed by professionals in those fields. Results: Two oncologists, two dieticians, and two nurses evaluated the AI’s performance across roles with 540 reviews. ChatGPT-4 excelled in data accuracy and completeness and was noted for its empathy and support, enhancing communication and reducing caregiver stress. It was potentially effective as a dietician. Discussion: This study offers preliminary insights into the feasibility of integrating AI tools like ChatGPT-4 into ePRO cancer care, highlighting its potential to reduce healthcare provider workload. Key directions for future research include enhancing AI’s capabilities in cancer care knowledge validation, emotional support, improving doctor-patient communication, increasing patient health literacy, and minimizing errors in AI-driven clinical processes. As technology advances, AI holds promise for playing a more significant role in ePRO cancer care and supporting shared decision-making between clinicians and patients.
Full article
(This article belongs to the Special Issue Feature Reviews in Section "Oncology Nursing")
►
Show Figures
Open AccessArticle
A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer
by
Danilo Giffoni de Mello Morais Mata, Rossanna C. Pezo, Kelvin K. W. Chan, Ines Menjak, Andrea Eisen and Maureen Trudeau
Curr. Oncol. 2025, 32(1), 6; https://doi.org/10.3390/curroncol32010006 - 25 Dec 2024
Abstract
Background: Anthracycline–taxane chemotherapy is the gold standard in high-risk breast cancer (BC), despite the potential risk of congestive heart failure (CHF). A suitable alternative for anthracycline-sparing chemotherapy is through the combination of docetaxel and cyclophosphamide (TC). Methods: Through a retrospective study of stage
[...] Read more.
Background: Anthracycline–taxane chemotherapy is the gold standard in high-risk breast cancer (BC), despite the potential risk of congestive heart failure (CHF). A suitable alternative for anthracycline-sparing chemotherapy is through the combination of docetaxel and cyclophosphamide (TC). Methods: Through a retrospective study of stage I-III HER2-negative BC, using administrative databases, we analyzed a total of 10,634 women treated with adjuvant chemotherapy in Ontario, Canada, between 2009 and 2017. We compared TC versus standardized anthracycline–taxane chemotherapies (ACT and FEC-D). We investigated the overall survival (OS), and explored the incidence of CHF, emergency department (ED) visits and febrile neutropenia. Results: With a median follow-up of 5.5 years, the 5-year analysis showed an increased OS in patients treated with TC, versus those treated with ACT, HR 0.77 (0.63–0.95, p = 0.015). Among ER + BC, there was an increased OS in patients treated with ACT and FEC-D, versus those treated with TC, HR 0.70 (0.52–0.95, p = 0.021) and HR 0.71 (0.56–0.91, p = 0.007), respectively. There were no substantial differences in CHF, between TC and anthracycline-based treatments. Patients treated with TC and FEC-D had more ED visits, compared to those treated with ACT. Conclusion: Our study shows that anthracycline–taxane regimens were the most commonly prescribed adjuvant chemotherapy options in HER2-negative BC. Women who received ACT had the lowest OS, likely due to their unfavorable pathology.
Full article
(This article belongs to the Section Breast Cancer)
Open AccessArticle
Improving Cancer Diagnosis in Alberta, Canada: A Qualitative Study of Emergency Department Healthcare Providers’ Perspectives on Diagnosing Cancer in the Emergency Setting
by
Anna Pujadas Botey, Cassandra Carrier, Eddy Lang and Paula J. Robson
Curr. Oncol. 2025, 32(1), 5; https://doi.org/10.3390/curroncol32010005 - 25 Dec 2024
Abstract
►▼
Show Figures
Cancer is the leading cause of death in Canada, with diagnoses increasing annually. In Alberta, many cancer cases are detected in emergency departments, often at advanced stages. Despite the significant role of emergency departments in cancer diagnosis, limited research exists on the experiences
[...] Read more.
Cancer is the leading cause of death in Canada, with diagnoses increasing annually. In Alberta, many cancer cases are detected in emergency departments, often at advanced stages. Despite the significant role of emergency departments in cancer diagnosis, limited research exists on the experiences of healthcare providers in this context. This qualitative study aimed to explore the perspectives of physicians and nurses working in emergency departments in Edmonton and Calgary regarding cancer diagnosis. Semi-structured interviews were conducted with 17 physicians and nurses, recruited through convenience and snowball sampling. Data collection continued until thematic saturation was reached. Interviews were analyzed thematically using an inductive, iterative process. Three main themes emerged: the acute care focus of the emergency department, its unsuitability for cancer diagnosis, and the need for systemic improvements to better support patients with suspected cancer. Participants highlighted challenges related to high patient volumes, the emotional burden of delivering cancer diagnoses, and barriers to effective communication and patient interaction in a fast-paced, high-pressure environment. The findings suggest the need for systemic reforms, including stronger primary care and improved care coordination, to alleviate pressure on emergency departments and enhance both patient outcomes and healthcare provider well-being.
Full article
Graphical abstract
Open AccessCase Report
Vulvar Metastasis in Renal Cell Carcinoma: A Case Report Highlighting the Aggressive Nature of Clear Cell Renal Cell Carcinoma
by
Andreea Boiangiu, Ana-Maria Cioca, Gabriel-Petre Gorecki, Romina-Marina Sima, Liana Pleș, Marius-Bogdan Novac, Ionut-Simion Coman, Valentin-Titus Grigorean, Vasile Lungu, Mihai-Teodor Georgescu and George-Alexandru Filipescu
Curr. Oncol. 2025, 32(1), 4; https://doi.org/10.3390/curroncol32010004 - 25 Dec 2024
Abstract
►▼
Show Figures
Vulvar cancer is one of the rarest gynecological malignancies. The development of this condition can be associated with either dysplasia linked to human papillomavirus (HPV), primarily affecting younger women, or vulvar dermatoses such as lichen sclerosus, which predominantly affect older women. Over the
[...] Read more.
Vulvar cancer is one of the rarest gynecological malignancies. The development of this condition can be associated with either dysplasia linked to human papillomavirus (HPV), primarily affecting younger women, or vulvar dermatoses such as lichen sclerosus, which predominantly affect older women. Over the last decade, the incidence of vulvar cancer has risen by 0.6% annually, while the relative survival rate has declined. Although metastasis to the vulva is uncommon, it can occur, particularly from cancers in nearby organs such as the cervix, bladder, rectum, or anus. More rarely, metastases from breast cancer and renal cell carcinoma have been reported in the vulva. Vaginal metastases from clear cell renal carcinoma are especially rare. In this article, we present the case of a 56-year-old patient diagnosed with clear cell renal carcinoma, who came to our clinic with a lesion on the right labia, which was identified as a metastasis originating from the kidney. Given the rarity of genital metastases in renal cancer, such cases should be examined and discussed to encourage further research and studies.
Full article
Figure 1
Figure 1
Open AccessReview
Nutritional Counseling During Chemotherapy Treatment: A Systematic Review of Feasibility, Safety, and Efficacy
by
Shalet James, Alexie Oppermann, Kaitlin M. Schotz, Mackenzie M. Minotti, Gautam G. Rao, Ian R. Kleckner, Brenton J. Baguley and Amber S. Kleckner
Curr. Oncol. 2025, 32(1), 3; https://doi.org/10.3390/curroncol32010003 - 24 Dec 2024
Abstract
Dietary interventions during chemotherapy hold promise for clinical and supportive care outcomes. We systematically investigated the feasibility, safety, and efficacy of nutritional counseling conducted during chemotherapy. Studies prospectively implemented nutrition counseling during chemotherapy. Articles were identified from three databases—EMBASE, Cochrane Library, and SCOPUS—from
[...] Read more.
Dietary interventions during chemotherapy hold promise for clinical and supportive care outcomes. We systematically investigated the feasibility, safety, and efficacy of nutritional counseling conducted during chemotherapy. Studies prospectively implemented nutrition counseling during chemotherapy. Articles were identified from three databases—EMBASE, Cochrane Library, and SCOPUS—from inception to 1 October 2024. Feasibility, safety, and efficacy of outcome data were extracted. Among 44 publications, 39 studies recruited 98 ± 80 participants (range 15–360); 38/39 (97%) were randomized controlled trials. One-third (31%) were among patients with breast cancer. Interventions were divided into individualized nutritional counseling (n = 21), nutrition counseling plus exercise (n = 13), and nutrient-specific dietary patterns (n = 10). Many had goals to achieve established nutrition guidelines. Feasibility was high based on attendance at counseling sessions, retention, and/or food log analysis. Overall, there were minimal adverse events related to the interventions. Many studies showed between-group differences favoring the intervention group for body weight (8/24, gain or loss, according to goals), nutritional status (8/9), quality of life (3/10 without and 6/9 with exercise), cancer-related fatigue (7/10), chemotherapy tolerance (6/11), and treatment responses (3/13). In conclusion, nutritional interventions were feasible and safe for patients undergoing chemotherapy and demonstrated preliminary efficacy to improve nutritional status, fatigue, chemotherapy tolerance, and other outcomes.
Full article
(This article belongs to the Special Issue Diet and Physical Activity Management during Cancer)
►▼
Show Figures
Graphical abstract
Graphical abstract
Open AccessArticle
Real-World Characterization of Toxicities and Medication Management in Recipients of CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma in Nova Scotia, Canada
by
Jenna Shaw, Mahmoud Elsawy, Rachel Nielsen, Amye Michelle Harrigan, Tara T. DiCostanzo and Laura V. Minard
Curr. Oncol. 2025, 32(1), 2; https://doi.org/10.3390/curroncol32010002 - 24 Dec 2024
Abstract
►▼
Show Figures
Nova Scotia (NS) began offering CAR T-cell therapy as a third-line standard of care for eligible patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) in 2022. Recipients of CAR T-cell therapy often experience acute toxicities, including cytokine release syndrome (CRS) and
[...] Read more.
Nova Scotia (NS) began offering CAR T-cell therapy as a third-line standard of care for eligible patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) in 2022. Recipients of CAR T-cell therapy often experience acute toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which require close monitoring and prompt management. This retrospective review aimed to describe the characteristics of adult patients with r/r LBCL deemed eligible to receive CAR T-cell therapy with axicabtagene ciloleucel in NS between January 2022 and June 2024, the toxicities experienced and toxicity management, hospital visits and intensive care unit (ICU) admissions, the utilization of toxicity management guidelines, and general efficacy outcomes. Twenty-seven patients received axicabtagene ciloleucel. All patients experienced CRS (7.4% grade ≥ 3), and 55.6% developed ICANS (25.9% grade ≥ 3). The median hospital stay was 18 days, with 40.7% requiring ICU admission. There was one treatment-related mortality. Most CRS (85.2%) and ICANS (80.0%) cases were managed according to the guidelines. By day +100, the best objective response rate was 81.5% (44.4% complete responses). Patients who received CAR T-cell therapy in NS, Canada, experienced comparable toxicities and efficacy to those reported in pivotal clinical trials and other real-world experiences.
Full article
Figure 1
Figure 1
Open AccessArticle
The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre
by
Anna-Maria Lazaratos, Matthew Dankner, Aalya Hamouda, Soumaya Labidi, Victor Cohen, Lawrence Panasci, Jennifer E. Friedmann, François Patenaude, Cristiano Ferrario, Mark Basik, April A. N. Rose and Parvaneh Fallah
Curr. Oncol. 2025, 32(1), 1; https://doi.org/10.3390/curroncol32010001 - 24 Dec 2024
Abstract
►▼
Show Figures
Background: Trastuzumab deruxtecan (TDXd) is an antibody–drug conjugate that has demonstrated impressive activity in randomized controlled clinical trials in the context of patients with HER2-amplified and HER2-low metastatic breast cancer. We aimed to review the activity and adverse event profile of TDXd in
[...] Read more.
Background: Trastuzumab deruxtecan (TDXd) is an antibody–drug conjugate that has demonstrated impressive activity in randomized controlled clinical trials in the context of patients with HER2-amplified and HER2-low metastatic breast cancer. We aimed to review the activity and adverse event profile of TDXd in heavily pretreated breast cancer patients in real practice. Methods: We describe a single-center retrospective case series of metastatic breast cancer patients who were treated with TDXd. The outcomes of interest were the overall response rate, overall survival, progression-free survival and grade 4–5 adverse events. Objective responses and PFS were assessed in accordance with RECIST 1.1 criteria. Results: We identified 38 patients treated with TDXd. Of these, 15 patients had classically defined HER2-positive (HER2+) breast cancer, 4 of whom had active central nervous system (CNS) metastases. A total of 23 patients had HER2-low breast cancer, 2 of whom had active CNS disease. Of the 33 patients evaluable for response, 21 (63%) patients had a response to treatment, including three (9%) complete responses. Outcomes were similar between patients with a HER2+ and HER2-low status, as well as in patients with or without CNS metastases. No patients experienced grade 4 or 5 toxicities, and four of thirty-eight patients (10.5%) experienced pneumonitis (two patients with grade 3 pneumonitis, one patient with grade 2 and one patient with grade 1), resulting in TDXd discontinuation for three patients (with steroid administration in two patients). Conclusions: TDXd demonstrates impressive activity with manageable adverse event profiles in this heavily pretreated population that includes patients with active CNS metastases.
Full article
Figure 1
Figure 1
Open AccessCase Report
Metabolic Complete Response of Metastatic Oncogene-Negative, PDL1-Negative Non-Small Cell Lung Cancer After Chemo-Immunotherapy and Radiotherapy: A Case Report
by
Alessia Surgo, Valerio Davì, Maria Paola Ciliberti, Roberta Carbonara, Morena Caliandro, Fiorella Cristina Di Guglielmo, Nicola Sasso, Roberto Calbi, Maria Annunziata Gentile, Tiziana Talienti, Isabella Bruno, Michele Troia, Ilaria Bonaparte, Giuseppe Mario Ludovico, Giammarco Surico and Alba Fiorentino
Curr. Oncol. 2024, 31(12), 8118-8126; https://doi.org/10.3390/curroncol31120598 - 23 Dec 2024
Abstract
A 71-year-old male ex-smoker presented in October 2021 to our department with a brain and bone metastatic adenocarcinoma NSCLC. PDL1, ROS, EGFR, and ALK were negative. He underwent stereotactic radiotherapy for brain metastases. In November 2021, he started a chemotherapy (CHT) regimen with
[...] Read more.
A 71-year-old male ex-smoker presented in October 2021 to our department with a brain and bone metastatic adenocarcinoma NSCLC. PDL1, ROS, EGFR, and ALK were negative. He underwent stereotactic radiotherapy for brain metastases. In November 2021, he started a chemotherapy (CHT) regimen with cisplatin (75 mg/m2 every 21 days) and pemetrexed (500 mg/m2 every 21 days), and ICI with Atezolizumab (1200 mg every 21 days). In July 2022, RT to the lung tumor and mediastinal nodal was performed with a total dose of 45 Gy in 15 fractions. He continued with immunotherapy until December 2022, when a grade 3–4 toxicity from immunotherapy was observed (hypothyroidism, psoriasis, and cystitis). He achieved a complete clinical response to the therapy. To date, the patient is alive, with a complete metabolic response, without treatment at 37 months from diagnosis.
Full article
(This article belongs to the Special Issue New Challenges and Advances in the Treatment of Lung Cancer: From Predictive Biomarkers to Minimally Invasive Techniques)
►▼
Show Figures
Figure 1
Figure 1
Open AccessArticle
Rural Versus Urban Genitourinary Cancer Incidence and Mortality in Pennsylvania: 1990–2019
by
Jonathan Pham, Ahmad N. Alzubaidi, Jay D. Raman and Tullika Garg
Curr. Oncol. 2024, 31(12), 8110-8117; https://doi.org/10.3390/curroncol31120597 - 23 Dec 2024
Abstract
Our aim was to describe the incidence and mortality of genitourinary (GU) cancers in rural and urban Pennsylvania counties. We calculated age-adjusted incidence and mortality rates of GU (prostate, bladder, and kidney) cancers from 1990 to 2019 in the Pennsylvania Cancer Registry. We
[...] Read more.
Our aim was to describe the incidence and mortality of genitourinary (GU) cancers in rural and urban Pennsylvania counties. We calculated age-adjusted incidence and mortality rates of GU (prostate, bladder, and kidney) cancers from 1990 to 2019 in the Pennsylvania Cancer Registry. We defined rurality using the Center for Rural Pennsylvania’s population density-based definition. We modeled average annual percent changes (AAPC) in age-adjusted incidence and mortality rates using joinpoint regression. Overall GU cancer incidence decreased in rural and urban counties (AAPC −7.5%, p = 0.04 and AAPC −6.6%, p = 0.02, respectively). Prostate cancer incidence decreased in rural and urban counties by −10.5% (p = 0.02) and −9.1% (p = 0.01), respectively. Kidney cancer incidence increased in both rural and urban counties, respectively (AAPC = +11.2, p = 0.002 and +9.3%, p = 0.01). GU cancer mortality decreased in rural and urban counties (AAPC = −11.6, p = 0.047 and AAPC −12.2, p = 0.01, respectively). Prostate cancer mortality decreased at similar rates in rural and urban counties (AAPC −15.5, p = 0.03 and −15.4, p = 0.02, respectively). Kidney cancer mortality decreased in urban (AAPC −6.9% p = 0.03) but remained stable in rural counties. Bladder cancer incidence and mortality were unchanged in both types of counties. Over three decades, GU cancer incidence and mortality decreased across Pennsylvania counties.
Full article
(This article belongs to the Section Genitourinary Oncology)
►▼
Show Figures
Figure 1
Figure 1
Open AccessReview
Let It Grow: The Role of Growth Factors in Managing Chemotherapy-Induced Cytopenia
by
Ruah Alyamany, Ahmed Alnughmush, Hazzaa Alzahrani and Mansour Alfayez
Curr. Oncol. 2024, 31(12), 8094-8109; https://doi.org/10.3390/curroncol31120596 - 21 Dec 2024
Abstract
Chemotherapy-induced cytopenia (CIC) is characterized by neutropenia, anemia, and thrombocytopenia, which are common and serious complications in cancer treatment. These conditions affect approximately 60% of patients undergoing chemotherapy and can significantly impact quality of life, treatment continuity, and overall survival. The use of
[...] Read more.
Chemotherapy-induced cytopenia (CIC) is characterized by neutropenia, anemia, and thrombocytopenia, which are common and serious complications in cancer treatment. These conditions affect approximately 60% of patients undergoing chemotherapy and can significantly impact quality of life, treatment continuity, and overall survival. The use of growth factors, including granulocyte colony-stimulating factors (GCSFs), erythropoietin-stimulating agents (ESAs), and thrombopoietin receptor agonists (TPO-RAs), has emerged as a promising strategy for managing CIC. However, the use of these growth factors must be approached with caution. This review provides an overview of the mechanisms, efficacy, and safety of growth factors in the management of CIC. Additionally, we discuss predictive markers for treatment response, potential risks, and highlight areas for future research.
Full article
Open AccessArticle
A Longitudinal Multimodal Imaging Study in Patients with Temporo-Insular Diffuse Low-Grade Tumors: How the Inferior Fronto-Occipital Fasciculus Provides Information on Cognitive Outcomes
by
Barbara Tomasino, Cinzia Baiano, Giuseppe Kenneth Ricciardi, Marta Maieron, Andrea Romano, Ilaria Guarracino, Miriam Isola, Maria De Martino, Serena D’Agostini, Daniele Bagatto, Teresa Somma, Miran Skrap and Tamara Ius
Curr. Oncol. 2024, 31(12), 8075-8093; https://doi.org/10.3390/curroncol31120595 - 20 Dec 2024
Abstract
Background: Tractography allows the in vivo study of subcortical white matter, and it is a potential tool for providing predictive indices on post-operative outcomes. We aim at establishing whether there is a relation between cognitive outcome and the status of the inferior fronto-occipital
[...] Read more.
Background: Tractography allows the in vivo study of subcortical white matter, and it is a potential tool for providing predictive indices on post-operative outcomes. We aim at establishing whether there is a relation between cognitive outcome and the status of the inferior fronto-occipital fasciculus’s (IFOF’s) microstructure. Methods: The longitudinal neuropsychological data of thirty young (median age: 35 years) patients operated on for DLGG in the left temporo-insular cortex along with pre-surgery tractography data were processed. Results: A degraded integrity of the left (vs. right) IFOF (lower fractional anisotropy and length, p < 0.001; higher mean and axial diffusivity, p < 0.01) was found, with lower microstructural variables in the infiltration (vs. dislocation) group. Significant decreases immediately post-surgery vs. pre-surgery mainly occurred in lexico-semantics (p < 0.001), with significant improvements at follow-up in all the tests (p < 0.01 to p < 0.001), despite values in the range of 44% to 47.82% of patients with below cut-off scores regarding naming verbs and making visual lexical decisions. The status of left and right IFOFs is predictive of a decrease in immediate post-surgery performance for several tests (p < 0.05); similarly, it is predictive of better recovery in the follow-up performance for naming nouns, naming verbs, making phonological fluency lexical decisions, and the token test (p < −0.05). For the ROC analysis, a significant result was obtained for the verb-naming test, with a cut-off of 79%. Conclusions: This study supports the role of the predictive value of pre-operative tractography for assessing the immediate post-operative result and at follow-up the risk of developing a cognitive deficit.
Full article
(This article belongs to the Section Neuro-Oncology)
►▼
Show Figures
Figure 1
Figure 1
Open AccessReview
Targeting TOP2A in Ovarian Cancer: Biological and Clinical Implications
by
Fulvio Borella, Stefano Fucina, Ylenia Seminara, Pietro Denti, Domenico Ferraioli, Luca Bertero, Niccolò Gallio, Jessica Cusato, Giorgio Valabrega, Alberto Revelli, Luca Marozio and Stefano Cosma
Curr. Oncol. 2024, 31(12), 8054-8074; https://doi.org/10.3390/curroncol31120594 - 20 Dec 2024
Abstract
The enzyme topoisomerase II alpha (TOP2A) plays a critical role in DNA replication and cell proliferation, making it a promising target for cancer therapy. In epithelial ovarian cancer (EOC), TOP2A overexpression is associated with poor prognosis and resistance to conventional treatments. This review
[...] Read more.
The enzyme topoisomerase II alpha (TOP2A) plays a critical role in DNA replication and cell proliferation, making it a promising target for cancer therapy. In epithelial ovarian cancer (EOC), TOP2A overexpression is associated with poor prognosis and resistance to conventional treatments. This review explores the biological functions of TOP2A in EOC and discusses its potential as a therapeutic target. We highlight studies on the mechanisms through which TOP2A contributes to tumor progression and recurrence. Additionally, we evaluate the clinical implications of targeting TOP2A, including the use of TOP2A inhibitors and their combination with novel drugs. We provide a comprehensive overview of the current understanding and future directions for targeting TOP2A in the management of EOC.
Full article
(This article belongs to the Section Gynecologic Oncology)
►▼
Show Figures
Figure 1
Figure 1
Open AccessArticle
Investigating Skin Cancer Risk and Sun Safety Practices Among LGBTQ+ Communities in Canada
by
François Lagacé, Farhan Mahmood, Santina Conte, Lorena A. Mija, Amina Moustaqim-Barrette, Jonathan LeBeau, Alyson McKenna, Mahan Maazi, Johnny Hanna, Alexandra Sarah Victoria Kelly, Raquel Lazarowitz, Elham Rahme, Travis J. Hrubeniuk, Ellen Sweeney and Ivan V. Litvinov
Curr. Oncol. 2024, 31(12), 8039-8053; https://doi.org/10.3390/curroncol31120593 - 19 Dec 2024
Abstract
►▼
Show Figures
Background: Skin cancer prevention relies on effective sun safety practices. Previous studies have shown that LGBTQ+ individuals exhibit lower sunscreen use and higher tanning bed usage compared to their non-LGBTQ+ counterparts. This study is the first to assess skin cancer risk factors, sun-protective
[...] Read more.
Background: Skin cancer prevention relies on effective sun safety practices. Previous studies have shown that LGBTQ+ individuals exhibit lower sunscreen use and higher tanning bed usage compared to their non-LGBTQ+ counterparts. This study is the first to assess skin cancer risk factors, sun-protective behaviors, and skin cancer concerns among LGBTQ+ individuals across Canada. Methods: A national survey study was conducted between July 2020 and March 2024 and included LGBTQ+ respondents aged ≥ 16 years who had completed the survey. Responses were summarized using frequency counts/percentages for categorical variables and means/standard deviations for continuous variables. Logistic regression models were used to calculate age- and gender-adjusted odds ratios for subgroup analyses. Results: Of the 700 LGBTQ+ participants included (59.3% women; median age 38 years), the majority had a Fitzpatrick skin phototype (FSP) I–III (76.4%). Concerningly, 60% reported >10 lifetime sunburns, 58% reported ≥1 blistering sunburn, 34% had used a tanning bed ≥1 time in their lifetime, and 69% reported having a tan in the last 12 months. Sunscreen was worn regularly by only half of the respondents, and half of the participants agreed or strongly agreed with “I look better and/or healthier with a tan”. Additional comparisons are presented based on gender, FSP, education, and income. Conclusion: The findings of this study highlight the need for public health campaigns tailored to the LGBTQ+ community, emphasizing culturally sensitive sun safety education, particularly for LGBTQ+ men, individuals with FSP IV–VI, and those with lower education levels, to help reduce future skin cancer risk.
Full article
Figure 1
Figure 1
Open AccessReview
Challenges in Implementing Comprehensive Precision Medicine Screening for Ovarian Cancer
by
Laura R. Moffitt, Nazanin Karimnia, Amy L. Wilson, Andrew N. Stephens, Gwo-Yaw Ho and Maree Bilandzic
Curr. Oncol. 2024, 31(12), 8023-8038; https://doi.org/10.3390/curroncol31120592 - 18 Dec 2024
Abstract
Precision medicine has revolutionised targeted cancer treatments; however, its implementation in ovarian cancer remains challenging. Diverse tumour biology and extensive heterogeneity in ovarian cancer can limit the translatability of genetic profiling and contribute to a lack of biomarkers of treatment response. This review
[...] Read more.
Precision medicine has revolutionised targeted cancer treatments; however, its implementation in ovarian cancer remains challenging. Diverse tumour biology and extensive heterogeneity in ovarian cancer can limit the translatability of genetic profiling and contribute to a lack of biomarkers of treatment response. This review addresses the barriers in precision medicine for ovarian cancer, including obtaining adequate and representative tissue samples for analysis, developing functional and standardised screening methods, and navigating data infrastructure and management. Ethical concerns related to patient consent, data privacy and health equity are also explored. We highlight the socio-economic complexities for precision medicine and propose strategies to overcome these challenges with an emphasis on accessibility and education amongst patients and health professionals and the development of regulatory frameworks to support clinical integration. Interdisciplinary collaboration is essential to drive progress in precision medicine to improve disease management and ovarian cancer patient outcomes.
Full article
(This article belongs to the Special Issue Ovarian Cancer in the Age of Precision Medicine)
►▼
Show Figures
Figure 1
Open AccessArticle
Development of a National Colorectal Cancer Screening Research Agenda: An Initiative of the Canadian Screening for Colorectal Cancer Research Network (CanSCCRN)
by
Cynthia Kendell, Robin Urquhart, Akua Kyei, Steven J. Heitman and Jill Tinmouth
Curr. Oncol. 2024, 31(12), 8010-8022; https://doi.org/10.3390/curroncol31120591 - 18 Dec 2024
Abstract
►▼
Show Figures
The Canadian Screening for Colorectal Cancer Research Network (CanSCCRN) recently set out to develop a national CRC screening research agenda and identify priority research areas. The specific objectives were to (1) identify evidence gaps relevant to CRC screening and the barriers and facilitators
[...] Read more.
The Canadian Screening for Colorectal Cancer Research Network (CanSCCRN) recently set out to develop a national CRC screening research agenda and identify priority research areas. The specific objectives were to (1) identify evidence gaps relevant to CRC screening and the barriers and facilitators to evidence generation and uptake by CRC screening programs, (2) establish high-priority collaborative research ideas to inform best CRC screening practices, and (3) identify one to two research topics for grant development and submission within 12 to 18 months. Three focus groups were conducted with network members and relevant parties (n = 15) to identify evidence gaps, barriers, and facilitators to evidence generation and uptake. Three workshops were subsequently held to discuss focus group findings and develop an action plan for research. An electronic survey was used to prioritize the evidence gaps to be addressed. Overall, five categories of barriers and six categories of facilitators to evidence uptake and generation were identified, as well as 23 evidence gaps to be addressed. Screening participation, post-polypectomy surveillance, and screening age range were identified as research priority research areas. Adequate resourcing and infrastructure, as well as partnerships with knowledge end users, are integral to addressing these research areas and advancing CRC screening programs in Canada and beyond.
Full article
Figure 1
Figure 1
Open AccessArticle
Breaking Barriers: Empowering Cervical Cancer Screening with HPV Self-Sampling for Sex Workers and Formerly Incarcerated Women in Toronto
by
Mandana Vahabi, Jenna Hynes, Josephine Pui-Hing Wong, Natasha Kithulegoda, Masoomeh Moosapoor, Abdolreza Akbarian and Aisha Lofters
Curr. Oncol. 2024, 31(12), 7994-8009; https://doi.org/10.3390/curroncol31120590 - 17 Dec 2024
Abstract
Background: Although cervical cancer (CC) is highly preventable through appropriate screening methods like the Papanicolaou (Pap) test, which enables early detection of malignant and precancerous lesions, access to such screening has not been equitable across social groups. Sex workers and people with records
[...] Read more.
Background: Although cervical cancer (CC) is highly preventable through appropriate screening methods like the Papanicolaou (Pap) test, which enables early detection of malignant and precancerous lesions, access to such screening has not been equitable across social groups. Sex workers and people with records of incarceration are among the most under-screened populations in Ontario. Little is known about the acceptability and feasibility of HPV self-sampling (HPV-SS) as an alternative cervical cancer screening method for these groups. This online, community-based mixed-methods pilot study aimed to address this knowledge gap. Methods: Eighty-four under- and never-screened sex workers and ex-prisoners aged 25–69 years and residing in the Greater Toronto Area, were recruited by community peer associates. Participants completed an online survey and viewed short videos about CC and screening with Pap and HPV-SS. Those who opted for HPV-SS conducted the test at one of two collaborating organizations. Results: The median age of participants was 36.5 years. Most had limited knowledge about CC and screening. Approximately 13% identified as non-binary, and 5% as two-spirit or trans men, with the majority having completed secondary education. Of the participants, 88% chose HPV-SS, and one-third tested positive for high-risk HPV types. The ability to self-sample without judgment from healthcare providers was noted as a key advantage. However, there was a need for training on proper HPV-SS techniques. Conclusions: To improve cervical cancer screening among sex workers, increasing awareness through participatory community co-creation of sexual health education is essential. Additionally, offering HPV-SS as a screening option is crucial, given its demonstrated acceptability and feasibility within this population, many of whom lack a primary care provider and face discriminatory attitudes in healthcare settings.
Full article
(This article belongs to the Special Issue Action and Impact: Prevention and Screening Strategies Contributing to the Elimination of Cervical Cancer)
►▼
Show Figures
Figure 1
Figure 1
Open AccessArticle
The Impact of a Breast Cancer Diagnosis on the Social Interaction Patterns of Young Omani Women: A Qualitative Study Approach
by
Mohammed Al-Azri, Zayana AL-Kiyumi, Khalid Al-Bimani and Huda Al-Awaisi
Curr. Oncol. 2024, 31(12), 7979-7993; https://doi.org/10.3390/curroncol31120589 - 16 Dec 2024
Abstract
Background and Aim: Young women diagnosed with breast cancer (BC) face considerable psychological and emotional distress, impacting their interactions with themselves, their families, and the wider community. This study sought to explore the interaction patterns of young Omani BC survivors following their diagnosis
[...] Read more.
Background and Aim: Young women diagnosed with breast cancer (BC) face considerable psychological and emotional distress, impacting their interactions with themselves, their families, and the wider community. This study sought to explore the interaction patterns of young Omani BC survivors following their diagnosis and during treatment. Materials and Methods: Semi-structured individual interviews were conducted with 11 Omani women diagnosed with BC, recruited from the Sultan Qaboos Comprehensive Cancer Care and Research Centre in Muscat, Oman. Participants were selected using purposive sampling to target Omani BC survivors aged under 45 years, with one to five years of survivorship post-diagnosis. Framework analysis was employed to analyse the qualitative data. Results: Six key types of interactions with various groups were identified: self, children, spouses, family, friends, and society. While many BC survivors demonstrated resilience through their strong faith, viewing the illness as part of a divine plan, others experienced diminished confidence and social withdrawal due to body image issues. Interactions with children centred on maintaining normalcy, while spouses typically provided emotional support despite challenges with intimacy. Family and friends offered crucial support, although concerns regarding societal stigma led some women to conceal their diagnosis. Conclusions: Participants in this study demonstrated a strong sense of acceptance of their cancer diagnosis as a result of their faith, viewing it as part of a divine plan. Their belief in divine guidance, paired with optimism about the available treatments, fostered resilience, allowing them to maintain a calm and hopeful outlook during their journey of treatment and recovery. However, some participants experienced a decline in self-confidence, particularly after treatment. This affected their willingness to socialise and interact with others, leading to introversion and a marked withdrawal from social interactions, often related to changed self-perception or fear of judgment following changes in appearance.
Full article
Open AccessReview
The Role of Stereotactic Body Radiotherapy in Oligometastatic Non-Small Cell Lung Cancer
by
Benson Wan and Magali Lecavalier-Barsoum
Curr. Oncol. 2024, 31(12), 7971-7978; https://doi.org/10.3390/curroncol31120588 - 15 Dec 2024
Abstract
Non-small cell lung cancer (NSCLC) is a major cause of mortality in Canada, with many patients presenting with metastatic disease. The oligometastatic state (OM-NSCLC) may be amenable to cure using aggressive local consolidative therapies. Stereotactic body radiotherapy (SBRT), which entails the utilization of
[...] Read more.
Non-small cell lung cancer (NSCLC) is a major cause of mortality in Canada, with many patients presenting with metastatic disease. The oligometastatic state (OM-NSCLC) may be amenable to cure using aggressive local consolidative therapies. Stereotactic body radiotherapy (SBRT), which entails the utilization of a high dose of radiation in one or few fractions, has many benefits in this setting, including its applicability in varied patient populations to ablate lesions in varied anatomical locations. It has also been demonstrated to prolong the time to next-line systemic therapy, to reduce financial burden, to improve quality-adjusted life years, and reduce adverse events caused by these lesions. This review outlines the published phase II and III trials that have already demonstrated the utility of SBRT in OM-NSCLC, as well as the many ongoing trials aiming to further define its role, including the largest phase II/III trial to date, NRG-LU002. Overall, SBRT appears to improve outcomes when combined with a broad range of standard-of-care therapies and is generally well tolerated; however, careful patient selection is necessary to maximize benefits while minimizing harm. Ongoing trials will help define the optimal patients for SBRT and the best timing for this intervention.
Full article
(This article belongs to the Special Issue Clinical Management and Outcomes of Lung Cancer Patients)
Open AccessArticle
The Influence of Nordic Walking Training on the Serum Levels of Sirtuins, FOXO3a, and Vitamin D Metabolites in Patients with Multiple Myeloma
by
Olga Czerwińska-Ledwig, Małgorzata Żychowska, Artur Jurczyszyn, Joanna Kryst, Adrianna Dzidek, Roxana Zuziak, Anna Jurczyszyn and Anna Piotrowska
Curr. Oncol. 2024, 31(12), 7960-7970; https://doi.org/10.3390/curroncol31120587 - 14 Dec 2024
Abstract
Background: Multiple myeloma, a malignancy of plasma cells, often involves the disruption of vitamin D metabolism. Vitamin D, acting through its receptor (VDR), affects transcription factors like FOXO and sirtuins, which regulate cellular processes. The impact of physical activity on these markers in
[...] Read more.
Background: Multiple myeloma, a malignancy of plasma cells, often involves the disruption of vitamin D metabolism. Vitamin D, acting through its receptor (VDR), affects transcription factors like FOXO and sirtuins, which regulate cellular processes. The impact of physical activity on these markers in multiple myeloma patients is unclear. Therefore, the objective of this study was to evaluate the effects of a 6-week training program on these parameters. Material and methods: The study was completed by 30 patients, including 16 in the Nordic walking training group (TG) and 14 in the control group (non-exercising, CG). All participants underwent a thorough medical interview before starting the project. Venous blood samples were collected from all participants four times—at baseline, after 3 weeks, after 6 weeks, and after 9 weeks (follow-up). The serum concentrations of sirtuin 1, sirtuin 3, Foxo3a, vitamin D receptor (VDR), 25(OH)D3, and 1,25(OH)2D were determined. Body composition, physical fitness, and physical activity level were assessed at baseline and after 6 weeks. Results: No statistically significant changes were observed in the serum levels of sirtuins, the FOXO3a protein, and 1,25(OH)2D. A statistically significant difference was observed in the levels of VDR for both time and group factors, but this was not confirmed in the post hoc test. Vitamin 25(OH)D3 level increased significantly in the study group with time. Conclusions: The applied 6-week Nordic walking training cycle positively affected the level of vitamin 25(OH)D3 but did not influence the rest of the biochemical parameters studied. The obtained results also indicate that the applied intervention is safe for patients and does not interfere with body composition.
Full article
(This article belongs to the Special Issue Diet and Physical Activity Management during Cancer)
►▼
Show Figures
Figure 1
Figure 1
Open AccessArticle
Education and Training Needs of Health Care Professionals in the Philippines Encountering Patients with Lung Oligometastatic Cancers
by
Daphne J. Valmonte, Naa Kwarley Quartey, Fatima Gutierrez, Janel Mendoza, Janet Papadakos and Meredith Giuliani
Curr. Oncol. 2024, 31(12), 7950-7959; https://doi.org/10.3390/curroncol31120586 - 13 Dec 2024
Abstract
►▼
Show Figures
This study aimed to examine the education and training needs of health care practitioners (HCPs) in the Philippines who encounter lung oligometastatic cancer patients. Lung oligometastatic disease is among the most common sites for cancer spread and has the most established practices for
[...] Read more.
This study aimed to examine the education and training needs of health care practitioners (HCPs) in the Philippines who encounter lung oligometastatic cancer patients. Lung oligometastatic disease is among the most common sites for cancer spread and has the most established practices for treating oligometastases. A modified version of the Hennessy–Hicks Training Needs Assessment Questionnaire was administered online to HCPs working in private and public centers in the Philippines. HCPs were recruited via purposive sampling. Twenty-seven HCPs completed the questionnaire (47% response rate). Respondents were mostly female (59%) and between the ages of 30 and 39 years (70%). Three-quarters (74%) were consultants, and most respondents were radiation oncologists (44%) or medical oncologists (30%). Medical oncologists rated Management/Supervisory Tasks (mean = 1.42) as their highest area of training need while radiation oncologists rated Clinical Tasks (mean = 1.30) as their highest training need. Pulmonologists (mean = 0.60) and other specialists (mean = 1.00) rated Administration tasks as their top area of training need. The clinical task-related category was rated the highest need among the continuing medical education topics. This study provides valuable insights for the implementation and advancement of a comprehensive curriculum in clinical oncology, specifically designed to enhance the administrative, clinical, and research capacities of oncologists who encounter oligometastatic lung disease in the Philippines.
Full article
Figure 1
Figure 1
Journal Menu
► ▼ Journal Menu-
- Current Oncology Home
- Aims & Scope
- Editorial Board
- Reviewer Board
- Topical Advisory Panel
- Instructions for Authors
- Special Issues
- Topics
- Sections & Collections
- Article Processing Charge
- Indexing & Archiving
- Editor’s Choice Articles
- Most Cited & Viewed
- Journal Statistics
- Journal History
- Journal Awards
- Society Collaborations
- Editorial Office
- 30th Anniversary
Journal Browser
► ▼ Journal Browser-
arrow_forward_ios
Forthcoming issue
arrow_forward_ios Current issue - Volumes not published by MDPI
Highly Accessed Articles
Latest Books
E-Mail Alert
News
Topics
Topic in
Cancers, Diagnostics, JCM, Pharmaceutics, Current Oncology
From Basic Research to a Clinical Perspective in Oncology
Topic Editors: Bianca Gǎlǎţeanu, Octav Ginghină, Ariana HuditaDeadline: 31 December 2024
Topic in
Biomedicines, Cancers, Current Oncology, Onco, Pathophysiology
Individualized Molecular Mechanisms and Treatment in Tumor Metastasis
Topic Editors: Dong Tang, Chen Liu, Bin ChengDeadline: 5 January 2025
Topic in
Cancers, Cells, JCM, Radiation, Pharmaceutics, Applied Sciences, Nanomaterials, Current Oncology
Innovative Radiation Therapies
Topic Editors: Gérard Baldacchino, Eric Deutsch, Marie Dutreix, Sandrine Lacombe, Erika Porcel, Charlotte Robert, Emmanuelle Bourneuf, João Santos Sousa, Aurélien de la LandeDeadline: 30 April 2025
Topic in
Biomedicines, Current Oncology, Diagnostics, Gastrointestinal Disorders, JCM
Advances in Gastrointestinal and Liver Disease: From Physiological Mechanisms to Clinical Practice
Topic Editors: Davide Giuseppe Ribaldone, Gian Paolo CavigliaDeadline: 20 June 2025
Conferences
Special Issues
Special Issue in
Current Oncology
Advancements in Clinical Trials in Oncology: Design, Enrichment, Safety, Operations, Patient Centricity, and Endpoints
Guest Editor: Brandon Michael HenryDeadline: 31 December 2024
Special Issue in
Current Oncology
2023–2024 Article Series of the Canadian Association of General Practitioners in Oncology
Guest Editor: Genevieve ChaputDeadline: 31 December 2024
Special Issue in
Current Oncology
Biliary Tract Cancer Updates: Advancements and Insights
Guest Editor: Kristen R. SpencerDeadline: 31 December 2024
Special Issue in
Current Oncology
An In-Depth Review of Desmoid Tumours
Guest Editor: Lloyd MackDeadline: 31 December 2024
Topical Collections
Topical Collection in
Current Oncology
New Insights into Prostate Cancer Diagnosis and Treatment
Collection Editor: Sazan Rasul
Topical Collection in
Current Oncology
New Insights into Breast Cancer Diagnosis and Treatment
Collection Editors: Filippo Pesapane, Matteo Suter
Topical Collection in
Current Oncology
Editorial Board Members’ Collection Series in "Exercise and Cancer Management"
Collection Editors: Linda Denehy, Ravi Mehrotra, Nicole Culos-Reed
Topical Collection in
Current Oncology
Editorial Board Members’ Collection Series: Contemporary Perioperative Concepts in Cancer Surgery
Collection Editors: Vijaya Gottumukkala, Jörg Kleeff